Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Hampshire: - New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
- Solinsky Center for Cancer Care — Manchester, New Hampshire
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in New Hampshire: - Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in New Hampshire: - Research Site — Laconia, New Hampshire
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Hampshire: - Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Hampshire: - Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New Hampshire: - Clinical Trial Site — Lebanon, New Hampshire
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New Hampshire: - NH Oncology-Hematology, PA - Payson Center for Cancer Care — Concord, New Hampshire
- Dana-Farber Cancer Insitute at Londonderry Hospital — Londonderry, New Hampshire
- Solinsky Center for Cancer Care (NH Oncology-Hematology, PA) — Manchester, New Hampshire
- New England Cancer Specialists - Portsmouth — Portsmouth, New Hampshire
Phase 2 Recruiting Academic/Other
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05716516
Sites in New Hampshire: - Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
Phase 1 Recruiting Industry
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06997029
Sites in New Hampshire: - Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
Phase 1 Recruiting Industry
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in New Hampshire: - Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in New Hampshire: - Research Site — Lebanon, New Hampshire